Wednesday, Novavax Inc NVAX reported fourth-quarter 2023 revenues of $291 million, down from $357 million a year ago, missing the consensus of $321.97…
Novavax Inc NVAX announced that peer-reviewed results from a Phase 3 efficacy trial of the R21/Matrix-M malaria vaccine were published in The Lancet…